المؤلفون: Wi TI, Won JE, Lee CM, Lee JW, Kang TH, Shin BC, Han HD, Park YM

المصدر: International Journal of Nanomedicine, Vol Volume 15, Pp 8427-8436 (2020)

مصطلحات موضوعية: linalool, liposome, ovarian carcinoma, doxorubicin, combination therapy, Medicine (General), R5-920

الوصف: Tae In Wi,1,* Ji Eun Won,1,* Chan Mi Lee,1 Jeong-Won Lee,2 Tae Heung Kang,1 Byung Cheol Shin,3 Hee Dong Han,1 Yeong-Min Park1 1Department of Immunology, School of Medicine, Konkuk University, Chungju 380-701, South Korea; 2Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; 3Bio/Drug Discovery Division, Korea Research Institute of Chemical Technology, Daejeon, South Korea*These authors contributed equally to this workCorrespondence: Hee Dong Han; Yeong-Min ParkDepartment of Immunology, School of Medicine, Konkuk University, 268 Chungwondae-Ro, Chungju, Chungcheongbuk-Do 380-701, South KoreaTel +82-2-2030-7848; +82-2-2049-6330Fax +82-2-2049-6192Email hanhd@kku.ac.kr; immun3023@kku.ac.krBackground: Epithelial ovarian cancer (EOC) is a fatal gynecologic malignancy that is usually treated with chemotherapy after surgery. However, patients who receive chemotherapy experience severe side effects because of the inherent toxicity and high dose of chemotherapeutics. To overcome these issues, we suggest a combination therapeutic strategy using liposomes encapsulating linalool nanoemulsions (LN-NEs) and doxorubicin (DOX), a chemotherapeutic drug, to increase their synergistic antitumor efficacy and reduce the incidence of side effects from chemotherapeutics for EOC.Methods: The physical properties of LN-NE-DOX-liposomes were characterized by light scattering with a particle size analyzer. Cell viability was determined by MTT assay. Therapeutic efficacy was evaluated in a mouse HeyA8 EOC tumor model of ovarian carcinoma. Additionally, biochemical toxicity was analyzed for levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and blood urea nitrogen (BUN) using BALB/c nude mice.Results: The size of the liposomes encapsulating LN-NEs and DOX (LN-NE-DOX-liposomes) was 267.0 ± 4.6 nm, with a loading efficiency of 55.1 ± 3.1% and 27.2 ± 0.9% for linalool and DOX, respectively. Cell viability after treatment with LN-NE-DOX-liposomes was significantly decreased compared to that of cells treated with DOX liposomes, and apoptosis was significantly increased. Additionally, LN-NE-DOX-liposomes significantly inhibited HeyA8 EOC tumor growth compared to that of the control (p < 0.01) and DOX-liposome-treated groups (p < 0.05), while decreasing cell proliferation (Ki67) and microvessel density (CD31), and promoting apoptosis (caspase-3) compared to the control (p < 0.05). Moreover, the liposomal formulations induced no significant differences in biochemical toxicity (AST, ALT, and BUN) compared to healthy control mice, indicating that the liposomal formulations showed no overt toxicity in mice.Conclusion: This study demonstrates that the production of LN-NE-DOX-liposomes is a pivotal approach for EOC treatment, suggesting a novel combination therapeutic strategy.Keywords: linalool, liposome, ovarian carcinoma, doxorubicin, combination therapy

وصف الملف: electronic resource

Relation: https://www.dovepress.com/efficacy-of-combination-therapy-with-linalool-and-doxorubicin-encapsul-peer-reviewed-article-IJN; https://doaj.org/toc/1178-2013

URL الوصول: https://doaj.org/article/89b064c93a4c4dcb84dc3c14865a1ed7

المؤلفون: Han HD, Byeon YS, Kang TH, Jung ID, Lee JW, Shin BC, Lee YJ, Sood AK, Park YM

المصدر: International Journal of Nanomedicine, Vol Volume 11, Pp 5729-5742 (2016)

مصطلحات موضوعية: dendritic cell, immunotherapy, nanoparticles, cancer, Medicine (General), R5-920

الوصف: Hee Dong Han,1,* Yeongseon Byeon,1,* Tae Heung Kang,1 In Duk Jung,1 Jeong-Won Lee,2 Byung Cheol Shin,3 Young Joo Lee,4 Anil K Sood,5–7 Yeong-Min Park1 1Department of Immunology, School of Medicine, Konkuk University, Chungwondaero, Chungju-Si, Chungcheongbuk-Do, 2Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 3Bio/Drug Discovery Division, Korea Research Institute of Chemical Technology, Yuseong-gu, Daejeon, 4Department of Bioscience and Biotechnology, Sejong University, Kwang-Jin-Gu, Seoul, South Korea; 5Department of Gynecologic Oncology and Reproductive Medicine, 6Department of Cancer Biology, 7Center for RNA Interference and Non-coding RNA, The University of Texas MD Anderson Cancer Center, TX, USA *These authors contributed equally to this work Abstract: Dendritic cells (DCs) are potent professional antigen-presenting cells that are capable of initiating a primary immune response and activating T cells, and they play a pivotal role in the immune responses of the host to cancer. Prior to antigen presentation, efficient antigen and adjuvant uptake by DCs is necessary to induce their maturation and cytokine generation. Nanoparticles (NPs) are capable of intracellular delivery of both antigen and adjuvant to DCs. Here, we developed an advanced poly(D,L-lactide-co-glycolide) (PLGA)-NP encapsulating both ovalbumin (OVA) as a model antigen and polyinosinic-polycytidylic acid sodium salt (Toll-like receptor 3 ligand) as an adjuvant to increase intracellular delivery and promote DC maturation. The PLGA-NPs were taken up by DCs, and their uptake greatly facilitated major histocompatibility class I antigen presentation in vitro. Moreover, vaccination with PLGA-NP-treated DCs led to the generation of ovalbumin-specific CD8+ T cells, and the resulting antitumor efficacy was significantly increased in EG.7 and TC-1 tumor-bearing mice compared to control mice (P

وصف الملف: electronic resource

Relation: https://www.dovepress.com/toll-like-receptor-3-induced-immune-response-by-polydl-lactide-co-glyc-peer-reviewed-article-IJN; https://doaj.org/toc/1178-2013

URL الوصول: https://doaj.org/article/90131cfb68714478bddecf9ebb19a0bd

المؤلفون: Park, J, Lee, H, Shin, BC, Lee, MS, Kim, B, Kim, JI

مصطلحات موضوعية: Complementary & Alternative Medicine

الوصف: © 2016 Jimin Park et al. Background. Pharmacopuncture is a new form of acupuncture combining acupuncture with herbal medicine, and it has been used under various conditions in Korea. The aim of this study is to establish clinical evidence for the safety and efficacy of pharmacopuncture in Korea. Methods. We searched 9 databases and two relevant journals up to December 2014 using keywords, such as pharmacopuncture. All randomized, controlled trials evaluating pharmacopuncture under any conditions in Korea were considered. Results. Twenty-nine studies involving 1,211 participants were included. A meta-analysis of two studies on obesity showed that 5 to 8 weeks of pharmacopuncture reduced weight, waist circumference, and body mass index (BMI) more than normal saline injections. In the 5 studies of musculoskeletal conditions, 7 to 30 days of pharmacopuncture had additional effects on the reduction of pain intensity, and this benefit was maintained by limiting analyses to studies with a low risk of bias for randomization and/or allocation concealment. Conclusions. This systematic review suggests the potential of pharmacopuncture for obesity and musculoskeletal diseases. However, it is difficult to recommend pharmacopuncture as an evidence-based treatment because of methodological flaws and small sample sizes of the included studies. Further well-designed trials are needed to draw a definitive conclusion.

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od_______363::7442519d52f234e7145ee0afa6f2b70d
https://hdl.handle.net/10453/89327

المؤلفون: Joon-Shik Shin, Jinho Lee, In-Hyuk Ha, Kim Mr, Soo Lee M, Shin Bc

المصدر: Pain. 155:202-203

مصطلحات موضوعية: Anesthesiology and Pain Medicine, Letter to the editor, Neurology, business.industry, Medicine, Neurology (clinical), business, Classics

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::12d55df161890422d645a5bad76001d3
https://doi.org/10.1016/j.pain.2013.09.010

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.